The effect of different concentrations of brachial plexus block with liposomal bupivacaine on postoperative pain in patients undergoing arthroscopic shoulder surgery: A Noninferiority Trial

开始日期2024-08-12

申办/合作机构

诸暨市人民医院

ChiCTR2400085180 / Suspended临床4期IIT

Comparison of the 95% effective dose of remimazolam versus propofol combined with low-dose esketamine for sedation during gastrointestinal endoscopy: a single-center randomized controlled trial

开始日期2024-06-10

申办/合作机构

诸暨市人民医院

100 项与诸暨市人民医院相关的临床结果

登录后查看更多信息

0 项与诸暨市人民医院相关的专利（医药）

登录后查看更多信息

项与诸暨市人民医院相关的文献（医药）

2024-09-15·Gut and Liver

Risk of Hematologic Malignancies in Patients with Inflammatory Bowel Disease: A Meta-Analysis of Cohort Studies

Article

作者: Tang, Linlin ; Ruan, Jiale ; Xiang, Zhiyi ; Wang, Dongying ; Zhou, Xiaoshuai ; Zhang, Qiufeng

Background/AimsInflammatory bowel disease (IBD) may contribute to the development of hematologic malignancies. In this study, the potential relationship between IBD and hematologic malignancies was investigated.MethodsWe searched the PubMed, Web of Science, Embase, and Cochrane Library databases for all cohort studies comparing the incidence of hematologic malignancies in non-IBD populations with that in IBD patients, and we extracted relevant data from January 2000 to June 2023 for meta-analysis.ResultsTwenty cohort studies involving 756,377 participants were included in this study. The results showed that compared with the non-IBD cohort, the incidence of hematologic malignancies in the IBD cohort was higher (standardized incidence ratio [SIR]=3.05, p<0.001). According to the specific types of IBD, compared with the non-IBD patients, the incidences of hematologic malignancies in ulcerative colitis patients (SIR=2.29, p=0.05) and Crohn's disease patients (SIR=3.56, p=0.005) were all higher. In the subgroup analysis of hematologic malignancy types, compared with the control group, the incidences of non-Hodgkin's lymphoma (SIR=1.70, p=0.01), Hodgkin's lymphoma (SIR=3.47, p=0.002), and leukemia (SIR=3.69, p<0.001) were all higher in the IBD cohort.ConclusionsThe incidence of hematologic malignancies, including non-Hodgkin's lymphoma, Hodgkin's lymphoma, and leukemia is higher in patients with IBD (ulcerative colitis or Crohn's disease) than in non-IBD patients.

2024-09-01·Journal of Computer Assisted Tomography

Predicting Microwave Ablation Early Efficacy in Pulmonary Malignancies via Δ Radiomics Models

Article

作者: Yang, Chen ; Feng, Jianju ; Zhao, Zhenhua ; Zhu, Fandong ; Yang, Jing

ObjectiveThis study aimed to explore the value of preoperative and postoperative computed tomography (CT)–based radiomic signatures and Δ radiomic signatures for evaluating the early efficacy of microwave ablation (MWA) for pulmonary malignancies.MethodsIn total, 115 patients with pulmonary malignancies who underwent MWA treatment were categorized into response and nonresponse groups according to relevant guidelines and consensus. Quantitative image features of the largest pulmonary malignancies were extracted from CT noncontrast scan images preoperatively (time point 0, TP0) and immediately postoperatively (time point 1, TP1). Critical features were selected from TP0 and TP1 and as Δ radiomics signatures for building radiomics models. In addition, a combined radiomics model (C-RO) was developed by integrating radiomics parameters with clinical risk factors. Prediction performance was assessed using the area under the receiver operating characteristic curve (AUC) and decision curve analysis (DCA).ResultsThe radiomics model using Δ features outperformed the radiomics model using TP0 and TP1 features, with training and validation AUCs of 0.892, 0.808, and 0.787, and 0.705, 0.825, and 0.778, respectively. By combining the TP0, TP1, and Δ features, the logistic regression model exhibited the best performance, with training and validation AUCs of 0.945 and 0.744, respectively. The DCA confirmed the clinical utility of the Δ radiomics model.ConclusionsA combined prediction model, including TP0, TP1, and Δ radiometric features, can be used to evaluate the early efficacy of MWA in pulmonary malignancies.

2024-08-14·Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

[Long-term hypomethylating agents in patients with myelodysplastic syndromes: a multi-center retrospective study].

Article

作者: Li, Y ; Yao, R X ; Zhang, H ; Jiang, W H ; Jin, J ; Du, X H ; Xiao, X B ; Ma, L Y ; Ouyang, G F ; Mei, C ; Huang, J ; Zhao, C F ; Zhang, J ; Yan, X F ; Wang, M L ; Jin, W M ; Huang, L ; Hu, T L ; Li, L J ; Zhou, S J ; Liu, X Z ; Luo, W J ; Jiang, L X ; Qian, S X ; Wu, G Q ; Zhou, M ; Le, J ; Fu, J P ; Jiang, H F ; Zhou, X P ; Tong, H Y ; Shou, L H ; Zhou, X J ; Lang, X H ; Zhang, Y ; Shao, Y P ; Zhang, Y D

目的： 研究去甲基化药物（HMA）足疗程治疗骨髓增生异常综合征（MDS）的疗效和安全性。 方法： 纳入来自浙江省45家医院的409例接受了至少连续4个周期的HMA单药起始治疗的MDS患者，评估HMA疗效和安全性。采用Mann-Whitney U或卡方检验比较组间临床资料差异，采用Logistic回归和Cox回归分析疗效与生存的影响因素，采用Kaplan-Meier法进行生存分析。 结果： 409例患者HMA治疗的中位疗程为6（4~25）个疗程。完全缓解（CR）率为33.98%，总缓解率（ORR）为77.02%。多因素分析显示，复杂核型（P=0.02，OR=0.39，95%CI 0.18~0.84）是CR的独立良好影响因素；TP53突变（P=0.02，OR=0.22，95%CI 0.06~0.77）是ORR的独立良好预测因素。患者的中位总生存（OS）时间为25.67（95%CI 21.14~30.19）个月，HMA治疗有反应（P=0.036，HR=0.47，95%CI 0.23~0.95）是OS的独立良好预后因素，而伴有复杂核型（P=0.024，HR=2.14，95%CI 1.10~4.15）、发生白血病转化（P<0.001，HR=2.84，95%CI 1.64~4.92）、TP53突变（P=0.012，HR=2.19，95%CI 1.19~4.07）均是OS的独立不良预后因素。HMA减剂量较标准剂量在疗效和中位OS时间均无显著差异。地西他滨和阿扎胞苷治疗组的CR率、ORR均无显著差异。接受地西他滨治疗患者的中位OS时间长于接受阿扎胞苷治疗患者（29.53个月对20.17个月，P=0.007），但地西他滨组严重骨髓抑制、肺炎发生率高于阿扎胞苷组。 结论： 在患者能够耐受情况下，连续规律地使用适当剂量的HMA，有利于MDS患者最大程度从治疗中获益。.

100 项与诸暨市人民医院相关的药物交易

登录后查看更多信息

100 项与诸暨市人民医院相关的转化医学

登录后查看更多信息